Cargando…

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional impairment in many people. While monoaminergic antidepressants have been used to effectively treat MDD, these antidepressants have limitations in that they have delayed onset of action and many patients remain tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Cheolmin, Kim, Yong-Ku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113176/ https://www.ncbi.nlm.nih.gov/pubmed/32209965 http://dx.doi.org/10.30773/pi.2019.0236

Ejemplares similares

The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Patho-physiological Mechanisms and Novel Treatments
por: Kim, Yong-Ku, et al.
Publicado: (2018)

Could ketamine be the answer to treating treatment-resistant major depressive disorder?
por: Ramadan, Abdullah Mohammed, et al.
Publicado: (2020)

The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder
por: Nugent, Allison C., et al.
Publicado: (2020)

Modulation of the functional connectome in major depressive disorder by ketamine therapy
por: Sahib, Ashish K., et al.
Publicado: (2022)

The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
por: Jeon, Sang Won, et al.
Publicado: (2018)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
por: Rong, Carola, et al.
Publicado: (2018)

Efficacy of different doses of ketamine as a bolus in major depressive disorder
por: Kheirkhah, Farzan, et al.
Publicado: (2018)

Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects
por: Sachdeva, Bhuvi, et al.
Publicado: (2023)

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
por: Hashimoto, Kenji
Publicado: (2014)

Major Depressive Disorder: Current Advances and Paradigm Shifts
por: Kim, Yong-Ku
Publicado: (2020)

Major depressive disorder: Validated treatments and future challenges
por: Karrouri, Rabie, et al.
Publicado: (2021)

Ketamine as Antidepressant? Current State and Future Perspectives
por: Hasselmann, H. W.W.
Publicado: (2014)

Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depressive Disorder
por: Kadriu, Bashkim, et al.
Publicado: (2017)

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
por: Yoon, Seoyoung, et al.
Publicado: (2016)

Characterization of Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder Using Ketamine as an Experimental Medicine Probe (†)
por: Albott, C. Sophia, et al.
Publicado: (2021)

The functional connectivity of the middle frontal cortex predicts ketamine’s outcome in major depressive disorder
por: Zhang, Fan, et al.
Publicado: (2022)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data
por: Shin, Cheolmin, et al.
Publicado: (2019)

Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
por: Davis, Margaret T., et al.
Publicado: (2021)

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
por: Ragnhildstveit, Anya, et al.
Publicado: (2022)

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder
por: Murrough, J W, et al.
Publicado: (2015)

The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
por: Schwartz, Orli S., et al.
Publicado: (2023)

Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”
por: Borentain, Stephane, et al.
Publicado: (2022)

Characteristics of Residual Symptoms in Korean Patients with Major Depressive Disorder: A Validation Study for the Korean Version of Depression Residual Symptom Scale
por: Park, Sol A, et al.
Publicado: (2018)

Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials
por: Li, Xiao-Mei, et al.
Publicado: (2020)

Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder
por: Liu, Haiyan, et al.
Publicado: (2023)

Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder
por: Zhan, Yanni, et al.
Publicado: (2020)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Antidepressant Effect of Combined Ketamine and Electroconvulsive Therapy on Patients With Major Depressive Disorder: A Randomized Trial
por: Shams Alizadeh, Narges, et al.
Publicado: (2015)

Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness?
por: Jeon, Sang Won, et al.
Publicado: (2016)

Ketamine for the treatment of major depression: a systematic review and meta-analysis
por: Nikolin, Stevan, et al.
Publicado: (2023)

Distinguishing Quantitative Electroencephalogram Findings between Adjustment Disorder and Major Depressive Disorder
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Ketamine Augmentation of Electroconvulsive Therapy: A Scoping Review of Dose-Dependent Effects in Major Depressive Disorder
por: Nagi, Tarika, et al.
Publicado: (2023)

Ketamine and depression: a narrative review
por: Corriger, Alexandrine, et al.
Publicado: (2019)

Ketamine treatment for depression: a review
por: Yavi, Mani, et al.
Publicado: (2022)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel, Philip F, et al.
Publicado: (2015)

Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder
por: Su, Yun-Ai, et al.
Publicado: (2022)

Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder
por: Park, Lawrence, et al.
Publicado: (2018)

Comparison of Clinical Features and Personality Dimensions between Patients with Major Depressive Disorder and Normal Control
por: Hur, Ji-Won, et al.
Publicado: (2009)

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
por: Ortega, Miguel A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u5a53ohhddk521oub8nh6poven